Gerlof D. Valk - Concepedia

Author

Gerlof D. Valk

Also Known As

G D Valk, G. D. Valk, G. Valk, G.D Valk, G.D. Valk, Gerlof D Valk, Gerlof D. Valk, Gerlof Dirk Valk, Gerlof Valk, Gerlof D. Valk

276

Publications

11.7K

Citations

H-Index

Concepts

All Affiliations

University Medical Center Utrecht University Medical Center Groningen Amsterdam UMC Location University of Amsterdam Radboud University Nijmegen Maastricht University

About

Gerlof D. Valk is an author at University Medical Center Utrecht specializing in medicine, pathology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	27	1.5K
2	Health Sciences	5	5	243
3	Public Health	3	3	57
4	Education	2	2	36
5	Social Sciences	2	2	46

Gerlof D. Valk

107

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors Paloma Cejas, Yotam Drier, Koen M.A. Dreijerink, Nature Medicine Tumor BiologyPancreatic CancerMedicineNeuroendocrine DisorderPathology	2019	179
Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study Frédéric Castinetti, Xiao-Ping Qi, Martin K. Walz, The Lancet Oncology Total AdrenalectomyEndocrine OncologyUrologyAdrenal GlandEndocrine Surgery	2014	178
Loss of ATRX or DAXX expression and concomitant acquisition of the alternative lengthening of telomeres phenotype are late events in a small subset of MEN-1 syndrome pancreatic neuroendocrine tumors Roeland F. de Wilde, Christopher M. Heaphy, Anirban Maitra, Modern Pathology Pancreatic CancerMedicineAlternative LengtheningTelomeres PhenotypePathology	2012	174
Long-Term Natural Course of Pituitary Tumors in Patients With MEN1: Results From the DutchMEN1 Study Group (DMSG) Joanne M. de Laat, Olaf M. Dekkers, Carolina R C Pieterman, The Journal of Clinical Endocrinology & Metabolism	2015	150
Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10 Karin Frank‐Raue, Lisa Rybicki, Zoran Erlic, Human Mutation	2010	149
Efficacy of α-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial Edward Buitenwerf, Thamara E. Osinga, Henri Timmers, The Journal of Clinical Endocrinology & Metabolism	2019	147
MEN1 redefined, a clinical comparison of mutation-positive and mutation-negative patients Joanne M. de Laat, Rob B. van der Luijt, Carolina R C Pieterman, BMC Medicine	2016	142
Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size Wenzel M. Hackeng, Lodewijk A.A. Brosens, Joo Young Kim, Gut	2021	138
The assessment of diabetic polyneuropathy in daily clinical practice: Reproducibility and validity of Semmes Weinstein monofilaments examination and clinical neurological examination Gerlof D. Valk, J. J. J. de Sonnaville, William H. van Houtum, Muscle & Nerve Daily Clinical PracticeNeurological DisorderDiabetesClinical NeurologyDiagnosis	1997	129
The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets Job van Riet, Harmen J.G. van de Werken, Edwin Cuppen, Nature Communications	2021	117

Page 1